Daiichi Sankyo
Cheng Zheng is a seasoned biostatistics professional with extensive experience in oncology development and statistical programming. Currently serving as Senior Director and Head of Biostatistics in Early Phase Oncology Development at Daiichi Sankyo, Inc. since February 2024, Cheng previously held leadership roles at Zentalis Pharmaceuticals as Vice President and Executive Director, overseeing biostatistics and statistical programming from May 2021 to February 2024. Prior experience includes positions at Sanofi, Novartis, and internships at Genentech and Roche Diagnostics. Cheng Zheng holds a Ph.D. in Statistics from Purdue University and a B.S. in Statistics from Peking University.
This person is not in any teams
This person is not in any offices
Daiichi Sankyo
21 followers
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.